SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-087326
Filing Date
2022-03-29
Accepted
2022-03-29 06:11:04
Documents
13
Period of Report
2022-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d302904d8k.htm   iXBRL 8-K 39839
2 EX-10.1 d302904dex101.htm EX-10.1 666973
  Complete submission text file 0001193125-22-087326.txt   980577

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA igms-20220328.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE igms-20220328_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE igms-20220328_pre.xml EX-101.PRE 11249
7 EXTRACTED XBRL INSTANCE DOCUMENT d302904d8k_htm.xml XML 3351
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

IRS No.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 22777306
SIC: 2834 Pharmaceutical Preparations